Physician profile
James S Lopez
NPI 1699206946
$2,776.70
in general payments reported to CMS, 2019-2025
40 companies · $774 in 2025
The $774 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.78 · 2022: $378 · 2023: $1,090 · 2024: $487 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.62 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $390.81 | 2022-2025 | Erleada, Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $342.94 | 2022-2025 | |
| Daiichi Sankyo INC. | $310.49 | 2022-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $190.55 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $177.21 | 2022-2024 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $102.33 | 2022-2025 | Enhertu, Lynparza |
| Beigene USA, INC. | $88.05 | 2023-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $83.03 | 2022-2025 | Xpovio |
| Pfizer INC. | $78.82 | 2023-2025 | |
| Celgene Corporation | $73.11 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $68.06 | 2024-2025 | |
| Genentech USA, INC. | $65.48 | 2022-2024 | Tecentriq, Polivy, Phesgo |
| Sobi, INC | $57.34 | 2023-2025 | |
| Incyte Corporation | $55.63 | 2023-2025 | Monjuvi, Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $54.27 | 2023-2024 | Jemperli, Zejula |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.